Irodalom:
1. Alfred King-Yin Lam, Said Saleh, Robert Anthony Smith, Yik-Hong Ho.: Quantitative analysis of survivin
in colorectal adenocarcinoma: increased expression and correlation with telomerase activity. Hum
Pathol. 2008;39(8):1229-1233.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R,
Patterson SD, Chang DD.: Wild-type KRAS is required for panitumumab efficacy in patients with
metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-34.
3. Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, DuBois RN.: Repression of
15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Cancer Res. 2008;68(22):9331-7.
4. Brandi G, Pantaleo MA, Biasco G, Paterini P.: Activated NF-kB in colorectal cancer: predictive or prognostic
factor? J Clin Oncol. 2008;26(8):1388-9; author reply 1389-90. Comment on: J Clin Oncol.
2007;25(25):3930-5.
5. Buisine MP, Wacrenier A, Mariette C, Leteurtre E, Escande F, Aissi S, Ketele A, Leclercq A, Porchet N,
Lesuffleur T.: Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch
repair-deficient colorectal cancers. World J Gastroenterol. 2008;14(7):1053-9.
6. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Menegaux F, Rosenzwajg M, Lemoine F,
Klatzmann D, Taieb J.: Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Gut. 2008 Dec 15. [Epub ahead of print]
7. Chien CW, Lin SC, Lai YY, Lin BW, Lin SC, Lee JC, Tsai SJ.: Regulation of CD151 by hypoxia
controls cell adhesion and metastasis in colorectal cancer. Clin Cancer Res. 2008;14(24):8043-51.
8. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E,
Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.: Relationship of circulating tumor cells
to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal
cancer. J Clin Oncol. 2008;26(19):3213-21.
9. Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P.: Common
polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis,
and survival. Mol Carcinog. 2008 Nov 13. [Epub ahead of print]
10. de Heer P, Koudijs MM, van de Velde CJ, Aalbers RI, Tollenaar RA, Putter H, Morreau J, van de Water
B, Kuppen PJ.: Combined expression of the non-receptor protein tyrosine kinases FAK and Src in
primary colorectal cancer is associated with tumor recurrence and metastasis formation. Eur J Surg
Oncol. 2008;34(11):1253-61.
11. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S, Bardelli A.: Wild-type BRAF is required for response to panitumumab or cetuximab
in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-12.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 245
246 Gastro Update 2009
12. Dong Y, Wang J, Sheng Z, Li G, Ma H, Wang X, Zhang R, Lu G, Hu Q, Sugimura H, Zhou X.:
Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod
Pathol. 2009;22(1):151-60.
13. Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P,
Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G. K-Ras: mutations and
treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer
Res. 2008;14(15):4830-5.
14. Fan LF, Dong WG, Jiang CQ, Qian Q, Yu QF.: Role of Hypoxia-inducible factor-1 alpha and Survivin
in colorectal carcinoma progression. Int J Colorectal Dis. 2008;23(11):1057-64.
15. Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H, Gerald W, Notterman DA, Barany F,
Paty PB.: MDM2 gene amplification is correlated to tumor progression but not to the presence of
SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res. 2008;6(2):205-11.
16. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M.:
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal
cancer: results from intergroup trial N9741. Clin Cancer Res. 2008;14(24):8263-9.
17. Furlan D, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, Uccella S, Bertolini V, Chiaravalli AM,
Capella C.: Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas.
Hum Pathol. 2008;39(10):1483-94.
18. Gao J, Knutsen A, Arbman G, Carstensen J, Franlund B, Sun XF.: Clinical and biological significance
of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis. 2008 Nov 25. [Epub ahead
of print]
19. Georgieva M, Krasteva M, Angelova E, Ralchev K, Dimitrov V, Bozhimirov S, Georgieva E, Berger
MR.: Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression
in colorectal cancer patients. Oncol Rep. 2008;20(1):3-11.
20. Gonçalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, Monges G, Bertucci F, Esterni B,
Delpero JR, Turrini O, Lelong B, Viens P, Borg JP, Birnbaum D, Olschwang S, Viret F.: A polymorphism
of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer
patients receiving cetuximab-based treatment. BMC Cancer. 2008;8:169.
21. Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, Odin E, Lindskog EB, Niyikiza C, Ma D.: Molecular
determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression
for 18 chemotherapy-related genes. Int J Cancer. 2009;124(5):1220-6.
22. Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T,
Matsuda S, Kitajima M, Kitagawa Y.: Clinical significance of circulating tumor cells in blood from
patients with gastrointestinal cancers.Ann Surg Oncol. 2008;15(11):3092-100.
23. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R,
McLeod HL, Baiget M.: Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer
Res. 2008;14(6):1788-96.
24. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny
WF, Hillan KJ, Koeppen H.: Association of k-ras, b-raf, and p53 status with the treatment effect of
bevacizumab. J Natl Cancer Inst. 2005;97(13):981-9.
25. Jorissen RN, Lipton L, Gibbs P, Chapman M, Desai J, Jones IT, Yeatman TJ, East P, Tomlinson IP,
Verspaget HW, Aaltonen LA, Kruhoffer M, Orntoft TF, Andersen CL, Sieber OM.: DNA copy-number
alterations underlie gene expression differences between microsatellite stable and unstable colorectal
cancers. Clin Cancer Res. 2008;14(24):8061-9.
26. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H,
Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras : mutations
Gastro 2009.qxd 5/9/2009 1:41 PM Page 246
A vastagbél 247
and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-65.
27. Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJ,
Guchelaar HJ.: GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC
patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer.
2008;99(8):1316-21.
28. Lam AK, Ong K, Ho YH.: Aurora kinase expression in colorectal adenocarcinoma: correlations with
clinicopathological features, p16 expression, and telomerase activity. Hum Pathol. 2008;39(4):599-604.
29. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjöblom T, Park BH, Parsons R,
Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio LA,
Wang TL, Markowitz SD, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE.: Integrated analysis
of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl
Acad Sci U S A. 2008;105(42):16224-9.
30. Liu HY, Zhou B, Wang L, Li Y, Zhou ZG, Sun XF, Xu B, Zeng YJ, Song JM, Luo HZ, Yang L.: Association
of E1AF mRNA expression with tumor progression and matrilysin in human rectal cancer. Oncology.
2007;73(5-6):384-8.
31. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson
PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.: Polymorphisms in cyclooxygenase-2
and epidermal growth factor receptor are associated with progression-free survival independent of K-ras
in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res.
2008;14(23):7884-95.
32. Macartney-Coxson DP, Hood KA, Shi HJ, Ward T, Wiles A, O’Connor R, Hall DA, Lea RA, Royds JA,
Stubbs RS, Rooker S.: Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted
in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level.
BMC Cancer. 2008;8:187.
33. Mammano E, Belluco C, Bonafé M, Olivieri F, Mugianesi E, Barbi C, Mishto M, Cosci M, Franceschi C,
Lise M, Nitti D.: Association of p53 polymorphisms and colorectal cancer: Modulation of risk and
progression. Eur J Surg Oncol. 2008 May 9. [Epub ahead of print]
34. Mûrkl B, Kerwel TG, Jûhnig HG, Oruzio D, Arnholdt HM, Schöler C, Anthuber M, Spatz H.: Methylene
blue-assisted lymph node dissection in colon specimens: a prospective, randomized study. Am J Clin
Pathol. 2008;130(6):913-9.
35. McCarty JH.: αv integrins lead the way for colorectal metastases. Clin Cancer Res. 2008;14(20):6351-3.
Comment on: Clin Cancer Res. 2008;14(20):6405-13.
36. Molnar B, Floro L, Sipos F, Toth B, Sreter L, Tulassay Z.: Elevation in peripheral blood circulating
tumor cell number correlates with macroscopic progression in UICC stage IV colorectal cancer
patients. Dis Markers. 2008;24(3):141-50.
37. Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA,
Schmoll SH, Porschen R, Schmiegel W, Graeven U; AIO Colorectal Study Group.: Predictive and prognostic
value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine
and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J
Colorectal Dis. 2008;23(11):1033-9.
38. Nakayama F, Semba S, Usami Y, Chiba H, Sawada N, Yokozaki H.: Hypermethylation-modulated
downregulation of claudin-7 expression promotes the progression of colorectal carcinoma. Pathobiology.
2008;75(3):177-85.
39. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS.: Circulating
25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol.
2008;26(18):2984-91. Comment in: J Clin Oncol. 2008;26(18):2937-9.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 247
248 Gastro Update 2009
40. Noike T, Miwa S, Soeda J, Kobayashi A, Miyagawa S.: Increased expression of thioredoxin-1, vascular
endothelial growth factor, and redox factor-1 is associated with poor prognosis in patients with liver
metastasis from colorectal cancer. Hum Pathol. 2008;39(2):201-8.
41. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS.:
Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol.
2008;26(35):5713-20.
42. Ohta M, Sugimoto T, Seto M, Mohri D, Asaoka Y, Tada M, Tanaka Y, Yamaji Y, Kanai F, Kawabe T, Omata M.:
Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. Hum
Pathol. 2008;39(9):1301-8.
43. Park JK, Hong R, Kim KJ, Lee TB, Lim SC.: Significance of p-STAT3 expression in human colorectal
adenocarcinoma. Oncol Rep. 2008;20(3):597-604.
44. Potocnik U, Glavac D, Dean M.: Common germline MDR1/ABCB1 functional polymorphisms and
haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet
Cytogenet. 2008;183(1):28-34.
45. Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, Samantas E, Xanthakis I,
Bobos M, Galanidi E, Bai M, Gikonti I, Koukouma A, Kafiri G, Papakostas P, Kalogeras KT, Kosmidis P,
Fountzilas G.: Potential value of PTEN in predicting cetuximab response in colorectal cancer: an
exploratory study. BMC Cancer. 2008;8:234.
46. Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Clarke SJ.: Thymidylate synthase
and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced
colorectal cancer patients. Clin Cancer Res. 2008;14(3):817-25.
47. Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Weiser MR, Franklin WA, Prendergast
FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD, Paty PB.: Immunohistochemical expression
of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol.
2008;39(4):498-505.
48. Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, Benjamin K, Hoda R, Krishna M,
Romano M, Wallace M, Garrett-Mayer E, Mitas M.: beta(2)microglobulin mRNA expression levels are
prognostic for lymph node metastasis in colorectal cancer patients. Br J Cancer. 2008;98(12):1999-
2005.
49. Sridhar SS, Goodwin PJ.: Insulin-Insulin-Like Growth Factor Axis and Colon Cancer. J Clin Oncol.
2008 Dec 8. [Epub ahead of print]
50. Vidaurreta M, Maestro ML, Sanz-Casla MT, Rafael S, Veganzones S, de la Orden V, Cerdán J, Arroyo
M, Torres A.: Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8.
Int J Colorectal Dis. 2008;23(6):581-6.
51. Wang G, Wang X, Wang S, Song H, Sun H, Yuan W, Cao B, Bai J, Fu S.: Colorectal cancer progression
correlates with upregulation of S100A11 expression in tumor tissues. Int J Colorectal Dis. 2008;
23(7):675-82.
52. Xie D, Ma NF, Pan ZZ, Wu HX, Liu YD, Wu GQ, Kung HF, Guan XY.: Overexpression of EIF-5A2 is
associated with metastasis of human colorectal carcinoma. Hum Pathol. 2008;39(1):80-6.
53. Yamada M, Ichikawa Y, Yamagishi S, Momiyama N, Ota M, Fujii S, Tanaka K, Togo S, Ohki S, Shimada H.:
Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer
Res. 2008;14(8):2351-6.
54. Yu K, Ganesan K, Tan LK, Laban M, Wu J, Zhao XD, Li H, Leung CH, Zhu Y, Wei CL, Hooi SC, Miller L,
Tan P.: A precisely regulated gene expression cassette potently modulates metastasis and survival in
multiple solid cancers. PLoS Genet. 2008;4(7):e1000129.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 248
A vastagbél 249
55. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y,
Culliford AT 4th, D’Alessio M, Barany F, Paty PB.: c-Met gene amplification is associated with
advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265(2):258-69.
56. Zhao L, Wang H, Li J, Liu Y, Ding Y.: Overexpression of Rho GDP-dissociation inhibitor alpha is associated
with tumor progression and poor prognosis of colorectal cancer. J Proteome Res. 2008;7(9):3994-4003.
57. Zlobec I, Baker K, Minoo P, Jass JR, Terracciano L, Lugli A.: Node-negative colorectal cancer at high
risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and
Raf-1 kinase inhibitor protein expression. Clin Cancer Res. 2008;14(1):143-8.
58. Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Beglinger C, Lugli A.: Two-marker protein profile
predicts poor prognosis in patients with early rectal cancer. Br J Cancer. 2008;99(10):1712-7.
59. Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, Lugli A.: Multimarker phenotype
predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer. 2008;
112(3):495-502.
60. Zlobec I, Terracciano LM, Lugli A.: Local recurrence in mismatch repair-proficient colon cancer predicted
by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res.
2008;14(12):3792-7.
